What is the AlloVir, Inc. stock price forecast?

AlloVir, Inc. is currently trading at $4.37. View real-time AI analysis on Alpha Lenz.

What is AlloVir, Inc. insider trading activity?

View the latest insider trading data for AlloVir, Inc. on Alpha Lenz.

What is AlloVir, Inc.'s P/E ratio?

View AlloVir, Inc.'s valuation metrics on Alpha Lenz.

AlloVir, Inc.

NASDAQ · KLRS

$4.37+0.10(+2.34%)Pre-market

Ask about AlloVir, Inc.'s future dividend policy...

Alpha Chat Insight

“AlloVir, Inc.'s ROE is -55.1%. Explore profitability and growth together.”

Ask for details →

Company Overview

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.

CEOMr. Andrew Oxtoby

Websitehttps://kalaristx.com

SectorHealthcare

IndustryBiotechnology

Employees14

Company Statistics

FY 2025

Profile

N/AMarket Cap

$0.00Revenue

0.00Shares Out

14Employees

Margins

N/AGross

N/AEBITDA

N/AOperating

N/APre-Tax

N/ANet

Valuation

N/AP/E

N/AP/B

N/AEV/Sales

N/AEV/EBITDA

N/AP/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-35.68%ROA

-55.11%ROE

-34.50%ROIC

Financial Health

$98.05MCash & Cash Equivalents

$-55.13MNet Debt

54.46%Debt/Equity

N/AInterest Cov